Table 3.
Anticancer activity of the O-alkyl derivatives of naringenin and their oximes.
| No. | HT-29 Cell Line IC50 (μg/mL) |
No. | HT-29 Cell Line IC50 (μg/mL) |
|---|---|---|---|
| NG | 38.93 ± 13.51 | NG-OX | 29.44 ± 3.16 |
| 1a | 24.98 ± 3.95 | 1b | 13.13 ± 1.02 |
| 2a | >100 | 2b | 11.45 ± 0.34 |
| 3a | 20.84 ± 2.05 | 3b | >100 |
| 4a | 14.82 ± 1.25 | 4b | 13.75 ± 2.09 |
| 5a | >100 | 5b | 7.65 ± 1.23 |
| 6a | >100 | 6b | >100 |
| 7a ★ | 11.99 ± 0.58 | 7b ★ | 9.11 ± 1.34 |
| 8a ★ | >100 | 8b ★ | 4.59 ± 0.56 |
| 9a ★ | 31.77 ± 6.00 | 9b ★ | >100 |
| 10a ★ | 10.41 ± 2.14 | 10b ★ | 7.26 ± 0.31 |
| 11a ★ | 9.81 ± 0.72 | 11b ★ | 4.89 ± 0.56 |
| 12a | 9.71 ± 1.28 | 12b ★ | 6.22 ± 0.30 |
| 13a ★ | >100 | 13b ★ | 3.32 ± 0.29 |
| 14a | 13.23 ± 0.61 | 14b | 7.00 ± 0.48 |
| 15a | >100 | 15b | 5.89 ± 1.29 |
| 16a | 8.35 ± 0.45 | 16b ★ | 3.63 ± 0.47 |
| 17a ★ | >100 | 17b ★ | >100 |
| 18a | 22.16 ± 4.33 | 18b | 7.46 ± 1.21 |
| 19a | >100 | 19b | >100 |
| Cisplatin | 16.73 ± 0.58 | ||
| Doxorubicin | 0.33 ± 0.02 | ||
★ novel derivatives of naringenin.